Novedosa therapy reduces hospitalization risk by 70%; also reduces the viral load of patients and the time to recover from illness.
The combination realized by the pharmaceutical company Eli Lilly of the synthetic anticoagulants reduces hospitalizations and deaths by covid-19 by 70% in high-risk patients with recent positive tests, the company said on March.
“Bamlanivimab and etesevimab together have the potential to be an important treatment that significantly reduces hospitalizations and deaths in patients with COVID-19 alto riesgo”, says Lilly’s Scientific Director, Daniel Skovronsky.
LEE TAMBIÉN: Two laboratories with car service for COVID-19 testing in San Salvador
The results were obtained from a phase 3 survey in which 1,035 people participated.
The treatment also reduces the viral load of the patients and the time to recover from the illness.
Patients are assigned a placebo or the combination of 2.8 grams each of the anticoagulants.
At least 11 deaths from hospitalizations among patients receiving treatment, 2.1% in this group.
In place, 36 deaths in hospitalizations, 7% of the group.
CONTINUES LEYENDO: Authorities for asylum Sara Zaldívar was quoted 9 weeks ago by the Assembly to inform hundreds of senior citizens of COVID and he was not charged
As such, the therapy represents a 70% reduction in risk. The result was statistically significant, which means that it is unlikely that it was registered for casualty.
Hubo 10 deaths in total, all between patients taking tombo and no one in the therapy group.
The company says it will continue to study the drug in another trial to examine if more doses are produced or the same impact.
The monoclonal antibodies are versions of the natural defenses of the body manufactured in the laboratory with the fight against infections.